恩替卡韦联合护肝布祖热颗粒治疗维吾尔族、汉族慢性乙型肝炎患者的疗效比较

发布时间：2018-07-15 20:23

【摘要】：目的比较恩替卡韦联合护肝布祖热颗粒治疗维吾尔族、汉族慢性乙型肝炎患者的临床疗效。方法采取前瞻性、配对研究方法,选取2015年1月至2015年5月新疆和田地区传染病医院就诊的初始治疗的慢性乙型肝炎患者为试验组,维吾尔族:汉族按照4:1配对分组,维吾尔族300例,汉族75例,均接受恩替卡韦联合护肝布祖热颗粒治疗12周,随机抽取20例汉族慢性乙型肝炎患者与80例维吾尔族慢性乙型肝炎患者为对照组,仅使用恩替卡韦治疗12周。观察各组患者病毒学应答率、血清学应答率、生物化学应答率以及不良反应发生率。结果治疗4周、8周、12周病毒完全应答率分别为:试验组中维吾尔族9.0%、20.7%、30.3%,汉族8.0%、21.3%、29.3%,对照组中维吾尔族2.5%、12.5%、21.3%,汉族5.0%、10.0%、20.0%;部分应答率分别为:试验组中维吾尔族48.3%、64.3%、69.3%,汉族46.7%、62.7%、64.0%,对照组中维吾尔族46.3%、62.5%、66.3%,汉族45.0%、65.0%、65.0%;生化学应答率分别为:试验组中维吾尔族88.7%、94.7%、99.3%,汉族85.3%、90.6%、98.6%,对照组中维吾尔族83.8%、87.5%、96.3%,汉族85.0%、90.0%、95.0%;血清学应答率分别为:试验组中维吾尔族31.7%、汉族29.3%、对照组中维吾尔族和汉族均为45.0%。治疗前后各组患者均未见明显脏器功能损伤。结论恩替卡韦联合护肝布祖热颗粒治疗维吾尔族慢性乙型肝炎患者的疗效比治疗汉族慢性乙型肝炎患者的疗效更好。
[Abstract]:Objective to compare the clinical efficacy of entecavir combined with Hugan Buzurie granule in the treatment of chronic hepatitis B in Uygur and Han nationality. Methods from January 2015 to May 2015, the patients with chronic hepatitis B (CHB) who were treated at the infectious disease hospital in Hetian region of Xinjiang were selected as the experimental group. The Uygur nationality: Han nationality were divided into two groups according to 4:1 pairing. 300 cases of Uygur nationality and 75 cases of Han nationality were treated with entecavir combined with Hugan Buzurie granule for 12 weeks. 20 patients with chronic hepatitis B of Han nationality and 80 patients with chronic hepatitis B of Uygur nationality were randomly selected as control group. Treatment with entecavir for 12 weeks only. The virological response rate, serological response rate, biochemical response rate and adverse reaction rate were observed. Results the complete response rates of the virus in the experimental group were as follows: in the test group, 9.0g and 20.7m, respectively, in the test group, in the control group, the Uygur group was 2.5-12.55.50.The partial response rates were as follows: in the test group, the Uygur nationality was 48.37.30% 64.34.33.The Han nationality was 46.7m and 62.7am 64.0, and the control group was 64.00.The partial response rates were as follows: in the test group, in the Uygur group, in the experiment group, in the control group. The biochemical response rates of the Uygur nationality in the experimental group were 88.7 / 94.74.70.The biochemical response rates were as follows: the biochemical response rates of the Uygur nationality in the experimental group were 88.7 / 94.74.799.30.The biochemical response rates of the Uygur nationality in the experimental group were 731.30, 29.3 respectively, and the control group was 83.87.56.36.30.The serological response rates of the Uygur nationality in the test group were 731.31. The Han nationality and the Han nationality in the control group were 731.30, 29.3and the control group, respectively. The biochemical response rates of the Uygur nationality in the experimental group were 731.30, 29.3 in the control group and 731.31 in the experimental group, respectively, in the control group, in the Uygur group, in the control group. Both er nationality and Han nationality were 45. 0%. Before and after treatment, there was no obvious injury of organ function in each group. Conclusion the curative effect of entecavir combined with Hugan Buzurei granule in treating Uygur patients with chronic hepatitis B is better than that of Han nationality patients with chronic hepatitis B.
【作者单位】：首都医科大学附属北京佑安医院急诊科;新疆和田地区传染病医院肝病科;
【基金】：中国初级卫生保健基金会资助项目(京佑基金【2015】第310号)
【分类号】：R512.62

【相似文献】